Daniel Geynisman
Fox Chase Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel Geynisman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:01 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07043972 · Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial CarcinomaFox Chase Cancer Center · recruiting · Urothelial Carcinoma · principal investigator
- Ph2NCT02614859 · Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer PatientsFox Chase Cancer Center · completed · Cancer of Prostate · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:01 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2021381 citationsRCR 18.5
- Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.J Clin Oncol · 2023200 citationsRCR 16.8
- Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.N Engl J Med · 2025147 citationsRCR 31.0
- Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer.J Clin Oncol · 2020118 citationsRCR 4.0
- Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).J Clin Oncol · 202582 citationsRCR 19.3
- 65 citationsRCR 7.4
- A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.Clin Cancer Res · 201762 citationsRCR 1.8
- 60 citationsRCR 5.4
- Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.Int J Radiat Oncol Biol Phys · 201739 citationsRCR 1.5
- A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.Clin Cancer Res · 202333 citationsRCR 2.4